Now, Tedder and colleagues help to resolve this issue by showing that B-cell depletion with a CD20-specific antibody has opposing effects on the severity of EAE depending on whether treatment is ...

An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...

Clinical studies with rituximab, a regulatory approved CD20-specific monoclonal antibody, have shown that B-cell depletion is efficacious in autoimmune diseases such as rheumatoid arthritis.

DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted ...

The potentially first-in-class drug, which targets CD20, is able to achieve "deep B-cell depletion" by stimulating cells of the immune system to engulf and destroy B-cells in the presence of a ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely focused on CAR-Ts and bispecifics, the German drugmaker has paid Cue ...

Nat Clin Pract Neurol. 2008;4(10):557-567. Rituximab can be administered intravenously at a dose of 375 mg/m 2, given weekly for 4 weeks, or in two 1 g infusions, given at fortnightly intervals ...

A single 600 mg BRIUMVI infusion on Day 1 was well tolerated in individuals with RMS regardless of prior treatment or B-cell depletion status Rapid 30-minute BRIUMVI infusions were well tolerated ...